Targeting histone deacetylases in testicular germ cell tumours: an encouraging treatment approach for the future.

Epidrugs, specifically histone deacetylase inhibitors (HDACis), have been increasingly used in pre-clinical studies for the treatment of testicular germ cell tumours (TGCTs). In a paper recently published in The Journal of Pathology, Jhuang et al. described SINHCAF as a potential oncogene in TGCTs located on chromosome 12p, the hallmark of type II (malignant) TGCTs. The findings contribute to the field by further supporting the efficacy of histone deacetylase inhibitors (HDACi) in the treatment of TGCTs, promoting the design of more pre-clinical studies and igniting the flame for future implementation of clinical studies with these compounds. This article is protected by copyright. All rights reserved.